Detected ·
Altay Therapeutics
$37MSeries A
Altay Therapeutics closed a $37M Series A to advance DX5057, an oral small molecule targeting DUX4 for FSHD, toward Phase 1 trials in Q1 2027.
- Website
- —
- linkedin.com/company/69914567
- Amount
- $37 000 000 USD
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-10-16 12:02:16 UTC
- Signal ID
- 95f620ef-188d-4168-bb8c-f670bbe00d34
As the API returns it
{
"id": "95f620ef-188d-4168-bb8c-f670bbe00d34",
"created_at": "2026-10-16T12:02:16.626327Z",
"company_name": "Altay Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/69914567",
"event_type": "funding",
"funding_amount": 37000000,
"funding_currency": "USD",
"funding_stage": "series_a",
"message": "*Altay Therapeutics closed a $37M Series A to advance DX5057, an oral small molecule targeting DUX4 for FSHD, toward Phase 1 trials in Q1 2027.*"
}